- Home
- SBRA
SBRA
Sabra Health Care REIT Inc.
as 06-04-2025 3:39pm EST
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $19.57 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 0.60 | EPS Growth: | 185.79 |
| 52 Week Low/High: | $13.87 - $20.03 | Next Earning Date: | 05-05-2025 |
| Revenue: | $720,247,000 | Revenue Growth: | 10.76% |
| Revenue Growth (this year): | 6% | Revenue Growth (next year): | 5.10% |
Stock Insider Trading Activity of Sabra Health Care REIT Inc. (SBRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| FOSTER MICHAEL J | SBRA | Director | May 20 '25 | Sell | $18.22 | 11,000 | $200,376.00 | 64,725 |
Latest Sabra Health Care REIT Inc. News
SBRA Breaking Stock News: Dive into SBRA Ticker-Specific Updates for Smart Investing
Business Wire
14 days ago
Sabra Health Care REIT, Inc. to Participate in Nareit’s REITweek 2025 Investor Conference and Attend ASHA’s 2025 Mid-Year Meeting
Argus Research
15 days ago
SBRA: What does Argus have to say about SBRA?
Argus Research
22 days ago
SBRA: What does Argus have to say about SBRA?
TipRanks
23 days ago
Sabra Health Care price target raised to $19 from $18 at Scotiabank
GuruFocus.com
a month ago
Sabra Health Care REIT Inc (SBRA) Q1 2025 Earnings Call Highlights: Strong Financial ...
Thomson Reuters StreetEvents
a month ago
Q1 2025 Sabra Health Care REIT Inc Earnings Call
Argus Research
a month ago
SBRA: What does Argus have to say about SBRA?
MT Newswires
a month ago
Sabra Health Care REIT Q1 Normalized AFFO, Revenue Rise
Compare SBRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SBRA Sabra Health Care REIT Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.